RENALYTIX AI PLC-ADR (RNLX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:RNLX • US75973T1016

0.2071 USD
+0.01 (+5.66%)
At close: Oct 7, 2024
0.13 USD
-0.08 (-37.23%)
After Hours: 10/7/2024, 8:16:27 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RNLX. RNLX was compared to 35 industry peers in the Health Care Technology industry. RNLX may be in some trouble as it scores bad on both profitability and health. RNLX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • RNLX had negative earnings in the past year.
  • RNLX had a negative operating cash flow in the past year.
  • RNLX had negative earnings in each of the past 5 years.
  • RNLX had a negative operating cash flow in each of the past 5 years.
RNLX Yearly Net Income VS EBIT VS OCF VS FCFRNLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

  • RNLX has a Return On Assets of -109.75%. This is amonst the worse of the industry: RNLX underperforms 89.19% of its industry peers.
  • RNLX has a Return On Equity of -250.48%. This is amonst the worse of the industry: RNLX underperforms 83.78% of its industry peers.
Industry RankSector Rank
ROA -109.75%
ROE -250.48%
ROIC N/A
ROA(3y)-76.55%
ROA(5y)-54.96%
ROE(3y)-138.17%
ROE(5y)-92.72%
ROIC(3y)N/A
ROIC(5y)N/A
RNLX Yearly ROA, ROE, ROICRNLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800

1.3 Margins

  • With a Gross Margin value of 20.60%, RNLX is not doing good in the industry: 86.49% of the companies in the same industry are doing better.
  • The Profit Margin and Operating Margin are not available for RNLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNLX Yearly Profit, Operating, Gross MarginsRNLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • RNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RNLX has more shares outstanding
  • The debt/assets ratio for RNLX is higher compared to a year ago.
RNLX Yearly Shares OutstandingRNLX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
RNLX Yearly Total Debt VS Total AssetsRNLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -5.75, we must say that RNLX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -5.75, RNLX is not doing good in the industry: 83.78% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.41 indicates that RNLX is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.41, RNLX is not doing good in the industry: 62.16% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z -5.75
ROIC/WACCN/A
WACC6.65%
RNLX Yearly LT Debt VS Equity VS FCFRNLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M

2.3 Liquidity

  • RNLX has a Current Ratio of 1.76. This is a normal value and indicates that RNLX is financially healthy and should not expect problems in meeting its short term obligations.
  • RNLX has a Current ratio (1.76) which is comparable to the rest of the industry.
  • RNLX has a Quick Ratio of 1.71. This is a normal value and indicates that RNLX is financially healthy and should not expect problems in meeting its short term obligations.
  • RNLX has a Quick ratio (1.71) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.76
Quick Ratio 1.71
RNLX Yearly Current Assets VS Current LiabilitesRNLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • RNLX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.23%, which is quite impressive.
  • RNLX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.58%.
EPS 1Y (TTM)27.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.99%
Revenue 1Y (TTM)14.58%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.35%

3.2 Future

  • RNLX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.35% yearly.
  • Based on estimates for the next years, RNLX will show a very strong growth in Revenue. The Revenue will grow by 73.89% on average per year.
EPS Next Y59.3%
EPS Next 2Y32.95%
EPS Next 3Y21.35%
EPS Next 5YN/A
Revenue Next Year39.85%
Revenue Next 2Y68.91%
Revenue Next 3Y73.89%
Revenue Next 5YN/A

3.3 Evolution

RNLX Yearly Revenue VS EstimatesRNLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
RNLX Yearly EPS VS EstimatesRNLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RNLX. In the last year negative earnings were reported.
  • Also next year RNLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNLX Price Earnings VS Forward Price EarningsRNLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNLX Per share dataRNLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RNLX's earnings are expected to grow with 21.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.95%
EPS Next 3Y21.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for RNLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RENALYTIX AI PLC-ADR

NASDAQ:RNLX (10/7/2024, 8:16:27 PM)

After market: 0.13 -0.08 (-37.23%)

0.2071

+0.01 (+5.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-15
Earnings (Next)10-29
Inst Owners4.26%
Inst Owner Change0%
Ins Owners6.06%
Ins Owner Change0%
Market Cap17.18M
Revenue(TTM)3.40M
Net Income(TTM)-46.22M
Analysts84
Price Target2.67 (1189.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)30.74%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.05
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 2.89
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.04
BVpS0.22
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -109.75%
ROE -250.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.6%
FCFM N/A
ROA(3y)-76.55%
ROA(5y)-54.96%
ROE(3y)-138.17%
ROE(5y)-92.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.76
Quick Ratio 1.71
Altman-Z -5.75
F-Score2
WACC6.65%
ROIC/WACCN/A
Cap/Depr(3y)34.78%
Cap/Depr(5y)392%
Cap/Sales(3y)44.23%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.99%
EPS Next Y59.3%
EPS Next 2Y32.95%
EPS Next 3Y21.35%
EPS Next 5YN/A
Revenue 1Y (TTM)14.58%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.35%
Revenue Next Year39.85%
Revenue Next 2Y68.91%
Revenue Next 3Y73.89%
Revenue Next 5YN/A
EBIT growth 1Y26.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.82%
EBIT Next 3Y19.78%
EBIT Next 5YN/A
FCF growth 1Y29.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.57%
OCF growth 3YN/A
OCF growth 5YN/A

RENALYTIX AI PLC-ADR / RNLX FAQ

What is the fundamental rating for RNLX stock?

ChartMill assigns a fundamental rating of 2 / 10 to RNLX.


What is the valuation status for RNLX stock?

ChartMill assigns a valuation rating of 1 / 10 to RENALYTIX AI PLC-ADR (RNLX). This can be considered as Overvalued.


What is the profitability of RNLX stock?

RENALYTIX AI PLC-ADR (RNLX) has a profitability rating of 0 / 10.


What is the financial health of RENALYTIX AI PLC-ADR (RNLX) stock?

The financial health rating of RENALYTIX AI PLC-ADR (RNLX) is 2 / 10.


What is the earnings growth outlook for RENALYTIX AI PLC-ADR?

The Earnings per Share (EPS) of RENALYTIX AI PLC-ADR (RNLX) is expected to grow by 59.3% in the next year.